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Delivery of RNA-based therapeutics to specific tissues for treating a variety of diseases faces 
many hurdles. But with several clinical trials and a slew of studies in animal models underway, the 
future of RNA-based therapeutics seems bright.In 1998, the US Food and Drug Administra-
tion (FDA) approved the first RNA-based 
drug for the treatment of a human disease. 
The drug, fomivirsen, is an antisense oligo-
nucleotide (oligo) that blocks synthesis of a 
key protein of cytomegalovirus. It is used 
to treat an inflammation of the eye caused 
by the virus.
Ten years later, although only one other 
RNA-based drug (an RNA aptamer) has 
made it to market, the arsenal of poten-
tial molecules and approaches contin-
ues to expand. It now includes a new 
generation of antisense oligos, aptam-
ers, ribozymes, RNA decoys, splice-site 
targeted oligos, small-interfering RNAs 
(siRNAs), short hairpin RNAs (shRNAs), 
and microRNAs (miRNAs) (see Review 
by T.A. Cooper, L. Wan, and G. Drey-
fuss in this issue of Cell). Although they 
all target RNA, these compounds work 
by distinct mechanisms. However, they 
share similar hurdles to clinical appli-
cation—the biggest of which is efficient 
delivery to the desired tissue.
Entering the Era of Clinical Trials
Antisense oligos like fomivirsen work by 
binding to a complementary sequence in 
an mRNA, thus preventing production of 
the protein encoded by that mRNA. When 
antisense oligos were first introduced as 
possible therapies, they were chemically 
modified to make the RNA more stable. “In 
spite of modifications the oligos still were 
not very effective [in knocking down gene 
expression] and had other unexpected 
effects,” says Ryszard Kole, senior vice 
president at AVI Biopharma (Corvallis, 
OR). However, advances in RNA chemis-
try have led to “second-generation” anti-
sense oligos with different modifications 
and improved activities.
Fomivirsen’s developer, Isis Pharma-
ceuticals (Carlsbad, CA), in collaboration 
with Genzyme (Cambridge, MA), recently launched one phase II and three phase 
III clinical trials of mipomersen. This 
second-generation antisense RNA drug 
reduces the production of apoB-100 (a 
protein critical for the synthesis and trans-
port of “bad cholesterol”) in patients with 
hypercholesterolemia. In addition, Isis 
has several other compounds in phase 
I trials including an antisense drug that 
targets C-reactive protein implicated in 
rheumatoid arthritis.
According to Isis president, Stan-
ley Crooke, many of the issues that 
plagued the original antisense drugs 
are no longer major challenges. “The 
oligos we use can be injected in the 
bloodstream and delivered to several 
tissues where they can persist for 14 
to 30 days, long enough to see a thera-
peutic response,” he says. However, 
not all tissues are amenable to delivery. 
“These oligos don’t cross the blood-
brain barrier, they don’t get into the 
heart and don’t get into muscle,” says 
Crooke. When administered subcuta-
neously, the Isis second-generation 
antisense drugs become localized in 
a variety of tissues including kidney, 
liver, and fat. As a result, clinical tri-
als have focused primarily on targeting 
diseases that involve systemic delivery 
to these tissues or, alternatively, tis-
sues that can be targeted by local oligo 
delivery (such as the eye or lung).
Several ongoing clinical trials are test-
ing RNA oligos that work by RNA inter-
ference (RNAi). These oligos are short 
double-stranded pieces of RNA, called 
siRNAs, that use the cellular machin-
ery—and in particular the RNA-induced 
silencing complex (RISC)—to degrade 
specific mRNAs before they can be 
translated into proteins.
In December 2008, Opko Health 
(Miami, FL) announced that it had com-
pleted enrollment of a phase II trial of the Cell 136, siRNA bevasiranib to treat age-related 
(“wet”) macular degeneration (AMD) 
caused by the abnormal growth of blood 
vessels behind the retina leading to vision 
loss. Bevasiranib targets the mRNA 
for vascular endothelial growth factor 
(VEGF), a protein that promotes blood 
vessel growth. The trial came under 
scrutiny when Jayakrishna Ambati at the 
University of Kentucky reported last year 
that many siRNAs, including bevasiranib, 
suppress blood vessel formation by acti-
vating an immune receptor called TLR3, 
suggesting that bevasiranib’s effect might 
be, at least in part, nonspecific.
Other companies are also conduct-
ing clinical trials of siRNAs for treating 
AMD. Interestingly, the only other FDA-
approved RNA-based drug is pegap-
tanib, an RNA oligo (aptamer) that blocks 
VEGF activity. Although approved for 
treating AMD, pegaptanib suffered from 
competition from a monoclonal antibody 
against VEGF made by Genentech.
But RNA therapeutics are also tar-
geting tissues beyond the eye. Alnylam 
Pharmaceuticals (Cambridge, MA) initi-
ated a phase II trial of an inhaled siRNA 
that targets lung epithelial cells to treat 
respiratory disease caused by syncytial 
virus infection. The company has two 
other drugs expected to go into clinical 
trials soon that will test systemic delivery 
of siRNAs to treat high blood cholesterol 
and liver tumors.
“In a very short time, Alnylam has 
shown that you could have systemic 
delivery, first in mice, then in monkeys, 
and the FDA just cleared the path for 
human trials,” says Thomas Tuschl, at 
The Rockefeller University and a member 
of Alnylam’s scientific advisory board.
Tuschl acknowledges that delivery of 
siRNAs to certain tissues is still a chal-
lenge. “Many studies are focusing on the 
mechanism of endocytosis, how RNAs February 20, 2009 ©2009 Elsevier Inc. 581
either alone or coupled with other mol-
ecules are taken up by cells,” he says. 
“Another interesting development is that 
you can force single-stranded RNA to go 
into RISC and act like siRNA. There are 
studies emerging to indicate that using 
single-stranded RNA may have some 
advantages.”
Small RNAs Steal the Limelight
Another class of small RNAs called 
miRNAs are produced inside cells. 
Each miRNA is thought to fine tune the 
expression of several mammalian genes. 
By using antisense oligos (called antag-
omirs) that target specific miRNAs, “we 
can regulate whole pathways or networks 
of genes. It is a whole different way of 
making drugs,” says Peter Linsley, CSO 
of Regulus Therapeutics, a joint venture 
between Isis and Alnylam.
A big challenge in developing miRNA-
based drugs is to identify which of the 
more than 8000 known miRNAs (http://
microrna.sanger.ac.uk/sequences) to 
target, but there are some good can-
didates. In December 2008, German 
scientists in collaboration with Regu-
lus reported that the miRNA miR-21 is 
overexpressed in human heart and that 
targeting this miRNA with an antago-
mir prevented heart failure in mouse 
models of heart disease. Another focus 
of the company is miR-122, an miRNA 
essential for the replication of hepatitis 
C virus. “The virus has less of a chance 
to develop resistance to a miRNA-based 
drug since the site targeted by this 
miRNA has been conserved. It should 
not contain residues that mutate read-
ily,” says Linsley.
Meanwhile, John Rossi’s group at City 
of Hope in Duarte, California and Benitec 
Inc. (Melbourne, Australia) are tackling 
HIV using another small RNA, an shRNA 
that silences gene expression through 
RNAi. Rossi and his team have engi-
neered a viral vector to carry this shRNA 
and deliver it to hematopoietic stem cells 
where it is incorporated into DNA. The 
shRNA is expressed forming a double-
stranded hairpin structure that is cleaved 
by the cellular machinery into an siRNA. 
Rossi’s shRNA targets two critical HIV 
genes; meanwhile, the viral vector trans-
porting the shRNA contains an RNA 
decoy that sequesters an HIV protein 
necessary for transcription of the viral 582 Cell 136, February 20, 2009 ©2009 Elsegenome. The viral vector also carries an 
RNA enzyme, called a ribozyme, which 
inactivates a cellular protein needed for 
HIV infection.
Although the ribozyme and RNA decoy 
are not as powerful as RNAi, Rossi says 
his group “did not want to use three dif-
ferent shRNAs because we did not want 
to overwhelm the cell machinery for 
RNAi. Instead, we used three different 
approaches.” As Rossi starts to use his 
triple-punch therapy in a pilot feasibility 
study in four HIV patients, one question 
is whether a cell’s RNAi system can be 
so overburdened that it eventually shuts 
down.
A challenge with shRNAs, as Mark 
Kay, director of human gene therapy at 
Stanford University, discovered, is that 
they can be toxic to cells when they are 
overexpressed. The solution is to use 
weak promoters to drive sufficient (but 
not too powerful) shRNA expression for 
a therapeutic effect. “If you are trying to 
target cholesterol or lipid, a 50%–80% 
reduction in gene expression is a great 
therapeutic effect,” says Kay.
To circumvent the problem of toxicity 
with shRNAs, gene therapy researcher 
Beverly Davidson at the University of Iowa 
placed the shRNAs into artificial miRNA-
based expression systems, before inser-
tion into an adenovirus-associated viral 
(AAV) vector. AAV has a natural attrac-
tion for neurons, and Davidson has used 
it to deliver shRNAs targeting the hun-
tingtin gene (mutated in Huntington’s 
disease) into the brains of mice with this 
neurodegenerative disorder. Her group, 
having shown that RNAi is therapeutic in 
two distinct mouse models of Hunting-
ton’s disease, is now gearing up for stud-
ies in nonhuman primates.
Phillip Zamore at the University of 
Massachusetts Medical School is also 
attempting to treat Huntington’s dis-
ease with RNAi but without viral vec-
tors. In 2007, Zamore and his collabo-
rator Neil Aronin showed that injecting 
mice with Huntington’s disease with an 
siRNA targeting huntingtin improved 
disease symptoms. He is now develop-
ing siRNAs that specifically target the 
huntingtin allele carrying the mutation 
but not the normal allele. Zamore says 
that there is at least one polymorphism 
in the huntingtin gene that segregates 
with the mutation in a majority of Hun-vier Inc.tington’s disease patients. Thus, it may 
be possible to design an RNA therapeu-
tic that targets the mutant allele of hun-
tingtin in a large number of Huntington’s 
patients, rather than having to design 
a different siRNA molecule for every 
patient.
The siRNA and shRNA strategies each 
have their own advantages and disad-
vantages. For example, siRNA treatment 
can be stopped at any time, but shRNA 
delivered with a viral vector remains in 
the tissue for the lifetime of the patient. 
But without the vector, delivery can be 
more challenging. “It is not clear that 
siRNAs are taken up by neurons or other 
cells in the brain, such as oligodendro-
cytes or astrocytes. So they may not be 
getting to the cells needed for therapy,” 
says Davidson. “Alternatively, we may 
find that therapeutic benefit requires 
targeting all cell types. Until more stud-
ies are done in rodent models and non-
human primates, we cannot know if that 
is needed or possible.”
Overcoming the Delivery Hurdle
“There are two considerations when 
choosing a target for RNA therapies,” 
says Rossi. “The first is the disease. Are 
there no other treatments for it? And 
AMD is a good example. The other con-
sideration is can we get the RNA triggers 
to the tissues affected by the disease? 
The liver, for example, is a good target, 
while tissues like the pancreas are more 
difficult.”
That does not mean that tissues for 
which delivery is more challenging can-
not be accessed. Swamy Manjunath at 
Harvard Medical School has used a short 
peptide derived from the rabies virus 
glycoprotein (which binds specifically to 
the acetylcholine receptor of neurons) 
to deliver siRNAs to mouse brain after 
intravenous administration. Once inside 
nerve cells, the siRNAs target Japanese 
encephalitis virus preventing the virus 
from causing fatal encephalitis in these 
animals.
Studies like these are showing promis-
ing results, but delivery continues to be 
a problem for the actual development of 
drugs that will be broadly beneficial to 
patients and that are of interest to large 
pharmaceutical companies. “I do see 
that delivery will continue to improve 
and the safety of the delivery systems 
will continue to improve, but right now 
we only see incremental changes. We 
would like to see a breakthrough,” says 
Alan Sachs, vice president of RNA thera-
peutics at Merck Co., Inc. (Whitehouse 
Station, NJ). In 2006, Merck acquired 
Sirna Therapeutics making a strong 
commitment to pursue the development 
of RNA-based therapies.
“We know the technology works quite 
well. The remarkable thing about siRNA 
is that it takes advantage of a natural 
mechanism to provide a very potent 
way of inhibiting RNA expression,” says 
Sachs. “But the question still is whether 
we can deliver this drug safely.” Delivery 
systems for siRNAs include peptides, 
polymers, and lipids bound to the RNA 
molecule, and each is associated with 
some toxicity. “Every drug has some 
toxicity at high enough doses,” explains 
Sachs. “We have to be able to develop 
compounds that can deliver siRNAs in 
sufficient amounts to have a high knock-
down effect, but with a sufficient margin 
of safety.”
Compared to delivery, other issues 
that need to be considered when 
designing siRNA-based therapies do 
not represent major challenges. “Deliv-
ery is by far the biggest problem,” says 
Zamore. “The other potential problems 
are vastly overstated.” One concern is 
off-target effects, whereby a particular 
siRNA will bind to mRNA targets other 
than the one it was originally designed 
against. But such nonspecific effects 
can be controlled by adding chemical 
modifications at certain positions in the 
siRNA. “Off-target effects are not as 
much of a problem today,” says Linsley. 
“To some extent you can predict what 
the off-target effects might be for a par-
ticular siRNA but they differ between pri-
mates and mice. You never really know 
what the problems might be until you 
go into humans.” Similarly, the immune 
response caused by siRNAs reported 
in some studies can be controlled by 
chemically modifying the siRNA.
However, stimulating the immune 
response may be, in some cases, ben-
eficial. “We use all the capabilities of an 
RNA molecule for functional activities,” 
says Gunther Hartmann of the Univer-
sity of Bonn, Germany. Hartmann has 
shown that an siRNA could decrease 
the expression of the Bcl2 gene, which is highly expressed in cancer cells and 
protects cells from undergoing apopto-
sis. By adding a triphosphate to the 5′ 
end of this siRNA, Hartmann made this 
molecule look like a virus to the immune 
system. The immune response against 
the siRNA worked synergistically with 
its silencing effect on Bcl2 to provoke 
large-scale death of lung tumor cells in 
a mouse model of metastatic cancer. 
“Effective tumor therapy requires differ-
ent activities so people think combina-
tion therapy is the way to go,” says Hart-
mann. “We have combined two activities 
in one molecule.”
Homing in on Splicing
One application for which siRNAs can-
not be used, but synthetic oligos are 
proving potentially valuable, is the modi-
fication of splicing to generate a new 
mRNA variant. Oligos used in this strat-
egy are chemically modified so that they 
are not recognized by the cellular RNAi 
or degradation machinery. AVI BioP-
harma’s Kole uses morpholinos—oligos 
with standard nucleic acid bases but 
bound to morpholine rings instead of 
deoxyribose or ribose sugars and linked 
through phosphorodiamidate groups 
instead of phosphates—coupled to 
arginine-rich cell-penetrating peptides 
in a variety of disease models. Kole has 
used these peptide-linked morpholinos 
to restore hemoglobin expression in a 
mouse model of the genetic blood dis-
ease, thalassemia. Mutations that cause 
thalassemia induce abnormal splicing of 
the β-globin gene encoding a hemoglo-
bin subunit. A morpholino that blocks an 
aberrant splice site in a mutant form of 
β-globin results in production of the cor-
rectly spliced β-globin mRNA.
Modifying aberrant splicing poten-
tially could correct the defect in sev-
eral other genetic diseases that can-
not be reversed by gene therapy. One 
such disease is Duchenne Muscular 
Dystrophy (DMD) caused by muta-
tions in a 2.4 Mb gene encoding the 
protein dystrophin, a critical structural 
component of muscle cells. The muta-
tions result in prematurely truncated, 
nonfunctional dystrophins. Annemieke 
Aartsma-Rus and colleagues at Leiden 
University use 2′-O-methyl-modified 
ribose oligos that cause the skipping of 
certain exons in the dystrophin mRNA Cell 136to restore a normal reading frame. This 
strategy results in the production of 
dystrophin proteins that are missing an 
internal exon but are partly functional, 
leading to a less severe phenotype. 
This group has published a study in 
four DMD patients showing that injec-
tion of a 2′-O-methyl-modified ribose 
oligo into muscle restored dystrophin 
synthesis in that muscle. The Dutch 
company Prosensa Therapeutics is 
now conducting a clinical trial to test 
systemic delivery of the same modified 
oligo in DMD patients. “The muscles 
are leaky because they do not pro-
duce dystrophin so the uptake is much 
higher than in normal muscle. So the 
disease is helping us with delivery,” 
says Aartsma-Rus. “In mice we get 
enough oligos in muscle to have a ben-
eficial effect.”
In January 2009, the MDEX Consor-
tium led by Francesco Muntoni at Uni-
versity College London, UK announced 
the results of a phase I clinical trial using 
a morpholino oligo to induce dystrophin 
production by exon skipping in the foot 
muscles of four boys with DMD. The 
group has now started a trial of sys-
temic delivery of the same oligo to DMD 
patients.
Next Generation Strategies
Because bacteria do not have a mech-
anism for RNAi, siRNAs cannot be 
used to silence bacterial genes. How-
ever, Nobel Laureate Sidney Altman at 
Yale University has developed a strat-
egy using peptide-linked morpholinos 
to inactivate bacterial genes. These 
oligos hybridize to the bacterial mRNA 
of choice to form specific complexes 
that then induce degradation of the 
target mRNA by the bacterial enzyme 
RNase P. “We have shown we can do it 
with Bacillus anthracis, Yersinia pestis, 
and other pathogenic bacteria,” says 
Altman. “We can inactivate them very 
quickly.”
A newer, and still somewhat con-
troversial, RNA-based molecule with 
possible therapeutic applications is 
antigene RNA (agRNA). AgRNAs are 
short double-stranded RNA molecules 
that do not target mRNAs but rather 
target gene promoters. These mol-
ecules either activate or inhibit gene 
expression in mammalian cells through , February 20, 2009 ©2009 Elsevier Inc. 583
an unknown mechanism. However, 
David Corey, at the University of Texas 
Southwestern Medical Center in Dallas, 
has shown that agRNAs specific for the 
progesterone receptor gene bind to 
antisense transcripts that overlap with 
the promoter for this gene. These agR-
NAs recruit proteins and trigger for-
mation of a large protein complex that 
includes transcription factors close to 
the progesterone receptor gene pro-584 Cell 136, February 20, 2009 ©2009 Elsemoter. Somehow, having a bulky com-
plex so close to the promoter has an 
effect on expression of this gene.
“The most obvious application of agR-
NAs is that you can use them to upregu-
late gene expression. There is currently 
no general way to do that with standard 
RNA technologies,” says Corey.
Understanding how RNA-based ther-
apies work is key if these approaches 
are to eventually succeed in the clinic. vier Inc.Results of several ongoing clinical tri-
als will show whether RNA-based 
therapeutics are set to become major 
players in the treatment of disease. “I 
think they will play a huge role in the 
therapeutic arena, but people have to 
be patient. If we proceed on a reason-
able path, the payoff could be great,” 
says Kay. “People have to realize that 
it takes time, but it is not from a lack of 
enthusiasm.”
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